Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

16. november 2026 oppdatert av: Longbio Pharma

A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Intervensjonell

Registrering (Antatt)

514

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Beijing, Kina
        • Peking Union Medical College Hospital
        • Ta kontakt med:
      • Shenyang, Kina
        • The First Affiliated Hospital of China Medical University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 75 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
  2. Male or female participant must be 12 to 75 years old at the time of ICF signature;
  3. Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
  4. Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
  5. Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
  6. Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
  7. Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.

Exclusion Criteria:

  1. The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
  2. Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
  3. Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
  4. Body weight < 40 kg
  5. Not enough washing-out period for previous therapy before randomization.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: LP-003 group

Participants received LP-003 subcutaneously during the 48-week treatment period

s.c. injection

Aktiv komparator: Omalizumab group

Participants received omalizumab subcutaneously during the 48-week treatment period

s.c. injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Tidsramme: Week 12

The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria.

Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
Tidsramme: up to approximately 56 weeks
up to approximately 56 weeks
The proportion of participants with UAS7 = 0 at each assessment visit
Tidsramme: up to approximately 56 weeks
up to approximately 56 weeks
The proportion of participants with UAS7 ≤ 6at each assessment visit
Tidsramme: up to approximately 56 weeks
up to approximately 56 weeks
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
Tidsramme: up to approximately 56 weeks

The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives.

up to approximately 56 weeks
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
Tidsramme: Time Frame: up to approximately 56 weeks

The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch.

Time Frame: up to approximately 56 weeks
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
Tidsramme: Time Frame: up to approximately 56 weeks

The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema.

Time Frame: up to approximately 56 weeks
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
Tidsramme: up to approximately 56 weeks

The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life

up to approximately 56 weeks
The incidence of adverse events during the study
Tidsramme: up to approximately 56 weeks

Incidence and severity of AE from first dose to end of study are recorded

up to approximately 56 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Xinghua Gao, First Hospital of China Medical University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

7. desember 2026

Primær fullføring (Antatt)

24. mars 2028

Studiet fullført (Antatt)

26. januar 2029

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere